Cerus

CERS

Market cap $486M

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for its full year and fourth quarter ended December 31, 2025. “Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world's blood supply. This past year, we achieved our highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components,” said William “Obi” Greenman, Ceru.

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the Company's management are scheduled to present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m. EST. A live webcast of the fireside chat will be accessible through the Investor Relations page of the Cerus website at http://www.cerus.com/ir. A replay will be available for 90 days after the event. ABOUT CERUS Cerus Corporation is dedicated solely to safe.

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today its fourth quarter and full-year 2025 financial results will be released on Monday, March 2, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor.

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced the start of the INITIATE study by the German Red Cross Blood Donation Service Baden-Württemberg – Hessen and its subsidiary organization, the German Red Cross Blood Donation Service North-East. The prospective, multicenter, non-interventional safety study, sponsored by DRK Blood Donation Service Baden-Württemberg-Hessen, is the first of its kind in Germany to evaluate the routine use of pathogen-inactivated plat.

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2025, as well as provided 2026 product revenue guidance and select milestones for 2026. “2025 was a remarkable year for Cerus, as patient access to INTERCEPT treated blood components increased meaningfully around the world,” said William “Obi” Greenman, Cerus' president and chief executive officer. “During 2025, based on the number of kits sold, we.

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that it has entered into a group purchasing agreement with Blood Centers of America (BCA), the largest blood supply cooperative in the U.S. BCA member blood centers produce approximately half of the U.S. platelet and cryoprecipitate supply. The agreement covers Cerus' entire INTERCEPT product line. Under this agreement, Cerus will partner with BCA to drive expanded access to pathogen reduction technology for plat.

CERS develops the Intercept Blood System for platelets, plasma, and IFC. These are valuable offerings for blood transfusions. CERS Intercept provides a pathogen-reduced transfusion product suite that directly address blood safety worldwide. IFC allows for room-temperature fibrinogen support that sharply reduces wasted product and turnaround times.

Cerus Corporation ( CERS ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Timothy Lee William Greenman - President, CEO & Chairman Vivek Jayaraman - Chief Operating Officer Kevin Green - VP of Finance & CFO Conference Call Participants Junwoo Park - Cantor Fitzgerald & Co., Research Division John Wilkin - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Cerus Corporation Third Quarter 2025 Earnings Conference Call.

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the third quarter ended September 30, 2025, and provided a business update. “We continue to make great strides in improving the safety and availability of transfused blood components around the globe and the record quarterly product revenue results reflect that progress. Product revenue growth was driven by strong global commercial execution and growing awareness of the benefits conferred by.

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that it will host an industry workshop on the benefits of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, commonly referred to as INTERCEPT Fibrinogen Complex, or IFC, at the 2025 Association for the Advancement of Blood and Biotherapies (AABB) Annual Meeting, taking place in San Diego, California from October 25 through October 28. The AABB Annual Meeting attracts healthcare professionals, scientists, and.